Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Leo must be close to something big if birthday reinforcement doom is heard.
Yes, it looks like back to active status again in Nevada.
https://esos.nv.gov/EntitySearch/BusinessInformation
Yes, and what percentage increase would that be, from .03 to 1.00?
What do you make of the very recent form 4 filing for one of the IPIX directors?
The tone of these questions for CEO Ehrlich sound rather demanding and demeaning, and we're all waiting to see if answers are forthcoming. Can you provide any "at this moment"? Or are we all simply waiting for the 10K?
You wouldn't want anyone to disclose non-public information in advance, would you?
There have been lots of disparaging arguments directed at CEO Ehrlich, including ones that harp on the company being suspect because merely a "one man band."
I suspect Leo has been working on the annual report, while also interacting with NIAID, NIH and the Military, getting ready for the conference last week, and perhaps taking calls of interest from Pharmas. The "very easy" recertification in Nevada shouldn't be hard to correct, once the very busy CEO gets to it (just ask Mrs. Ehrlich).
Demanding to know "at this moment" about the readiness of the annual report, who is in it, and the temporary lapse of good standing, won't make the information available any sooner, so we'll all have to wait a few days more. We'll also find out about any hypothetical "default standing" which actually doesn't seem to have affected shares trading in a "marketplace" that is not a real "exchange."
Let us know if an NT gets filed. It sometimes happens to small companies who are "one man bands" with lots on their plate. Unless the belief is that Leo is still poolside sipping a drink?
Funny thing is, all is forgiven if one or more deals get struck, or funding is obtained. Do you think that might happen in the next month or two?
Are there any questions about the number of viruses Brilacidin effectively inhibits in vitro?
Any idea if the military has been quietly testing the drug?
This post is in response to:
Meanwhile... quiet accumulation continues...
With 3 successful PH-2 clinical trials using "B" and NIH/NIAID ongoing research on 20+ pathogens, one wonders when funding or partnership will be announced.
Over $2 per share in the blink of an eye in that case
Is this company going to get bought out?
So NIH and NIAID have shown increasing interest researching Brilacidin as an anti-viral at the same time as a provider/payer analysis has been completed for a possible PH-3 partnership for Oral Mucositis, and the company's Nevada charter has been allowed to lapse?
Interesting combo of events... and we should know the whys and wherefores by the time the 10K is filed.
'The 2022 Military Health System Research Symposium Abstract' contains their pathogens of concern:
Quote:Introduction: Acutely infectious viruses, including those transmissible by the respiratory and aerosol routes, pose critical threats to the warfighter and the civilian population. Aerosol-transmissible pathogens, such as bunyaviruses (Rift Valley fever virus [RVFV]), and alphaviruses (Venezuelan Equine Encephalitis Virus [VEEV], Eastern Equine Encephalitis Virus [EEEV]), have a broad range of host tropism, retain high rates of infectivity as aerosols, attain high viral load in the host over short periods, cause damage to the blood-brain barrier (BBB), impact neurological integrity and are likely to contribute to organ damage due to extreme inflammation. These viruses pose nontrivial challenges to the warfighter because no FDA-approved therapeutics or vaccines are currently available that can be rapidly scaled up, field-deployed, and thus potentially mitigate the harmful consequences of inflammation in addition to decreasing viral load. The long-term neurological sequelae that can ensue from these acute viral infections, especially by the aerosol route, can lead to a life-long health burden for the warfighter. These pathogens are also naturally transmitted by mosquito vectors. They are known to cause zoonotic diseases in animals and affect humans annually in the United States and other parts of the world. This situation could further drive mutations, leading to infectious spillover events between species. There is an urgent, unmet need for broad-spectrum intervention strategies that can ideally control the disease manifestations in the host and the spread of disease as a prophylactic countermeasure. Our ongoing studies with brilacidin, a host defense peptide (HDP)-based mimetic, have successfully demonstrated that brilacidin can interfere with viral integrity and exert an antiviral effect in vitro against candidate alphaviruses and bunyavirus. Furthermore, early indications support the potential of brilacidin to also act in an anti-inflammatory capacity by its impact on inflammatory cytokine expression.
http://www.ipharminc.com/new-events-and-presentations/2022/8/8/2022-military-health-system-research-symposium
While, IMO, a collaboration with the military doesn't make financial sense for IPIX at this time, IPIX's poster presentation at the 2022 MHSRS makes all the sense in the world. It will put Brilacidin higher on the military's 'radar' and lay the groundwork for future collaboration.
https://mhsrs.health.mil/SiteCollectionDocuments/2022_MHSRS_Poster_Sessions.pdf
It is quite conceivable that IPIX's collaboration with NIAID could lead to IPIX gaining the wherewithal to enter into business agreement(s) with the military to co-develop therapeutics for their pathogens of concern. That NIAID has already tested "B" against viral families (Alphaviruses, Bunyavirus) of concern to the military suggest that any later agreement(s) between IPIX and the military will be less costly to IPIX than if NIAID had done no initial testing and research.
http://www.ipharminc.com/press-release/2022/6/28/innovation-pharmaceuticals-announces-new-antiviral-research-on-brilacidin-in-bunyaviruses-and-alphaviruse
Link back for more information, thanks to CMC for these quotes and thoughts.
Last Nov. 2021 when primary endpoints were not met in the Covid trial, the stock price crashed.
The reverse will happen with news of a partnership or licensing agreement.
Evidence for pharma to take a stake in Brilacidin increases with every peer reviewed article published.
With baby bios like IPIX, it often takes a long time for everything to happen all at once!
Important Distinctions Between NIAID And The Military (MHSRS)
The distinction is that NIAID will pay Brilacidn's early antiviral development costs and the military will share ALL B-AV development costs with IPIX.
Link back for good information about IPIX and ongoing research.
It's quite likely IPIX drugs will be clinically successful and widely adopted.
PH-3 Brilacidin for Oral Mucositis is on deck IMO.
From 5 weeks ago:
https://www.ipharminc.com/press-release/2022/7/22/provider-and-payer-analysis-supports-potential-commercialization-of-innovation-pharmaceuticals-brilacidin-as-a-novel-oral-mucositis-drug-candidate
Reality...
"From human trials so far it is most probable Brilacidin works for oral mucositis and ABSSSI and ulcerative proctitis. From smaller human trial plus in vitro tests it is possible Brilacidin works for inflammatory bowel disease and as a broad spectrum anti-viral."
Everyone knows that IPIX needs a licensing and/or partnership to fund a PH-3 clinical trial.
Given the 3 separate successful PH-2 clinical trials and current positive testing results from NIAID/NIH related researchers, I suspect IPIX will either land a significant partnership, get funded by Gov. entity, or get bought out by a pharma for significantly more than the current SP.
From earlier this month:
https://www.ipharminc.com/press-release/2022/8/5/innovation-pharmaceuticals-announces-nihniaid-affiliated-researchers-to-evaluate-brilacidins-treatment-potential-against-monkeypox
More than a passing acquaintance?
There is so much talk about CEO Ehrlich's "faults," so am curious.
The argument that CEO Ehrlich is coasting on his salary and this is his top and singular priority is complete bullshit.
I called attention to the large blocks that keep going off at the ask, because they suggest someone is accumulating. Daily golden cross should follow the weekly, thanks for pointing it out.
It's not a lot of money for some to buy 100K shares at this low share price, but I guess the prospect that a partnership might be in the works is frightening enough to provide grist for the mill for ridiculing everything about the company, including the CEO and his "salary." A tired argument used against many OTC companies.
All while NIAID and NIH continue to research Brilacidin for 20+ indications and counting.
And there aren't many good alternatives for severe OM that B has been shown to help in a successful PH-2 clinical trial.
... And that golden cross gets closer and closer
I see another 100K buy went off at the ask earlier today.
Somethin' cookin' ?
Full-court press won't stop a partnership for B-Om if one is being negotiated.
It has been many months with no evidence forthcoming? To me that means there is no basis for the assertion:
"...nobody is going to give a 5 day IV course that causes severe hypertension"
in response to:
NIAID's continued interest and testing of B supports your line of reasoning. And NIAID certainly has the money to make things happen.
Your post should be stickied... thanks for putting it together.
Interesting how those large blocks on the bid keep showing up unexpectedly... and almost daring the MMs to sell to them.
Let's see if the bid gets jumped or the ask gets hit end of day.
I'm waiting for a possible B-OM deal to be announced, given recent news.
Amusing to watch the MMs lowering the ask bit by bit, to entice buyers to bite.
At the same time they jump legitimate bids to keep the large blocks on the bid from getting hit.
Also... notice that the largest block of the day (so far) 225,000 went off near the high at .048
Let's see what "they" do at the close.
This post should be stickied... excellent job CMC!
some excerpts follow, but the whole post should be read.
Question of the day: Does affiliated, or affiliation, or collaboration mean "working for..."? I'm not sure anyone can answer that question until there is news of funding.
For anyone who wants to know more about the word "affiliated," common synonyms are "connected, joined, related..."
Ehrlich reported it this way on June 23, 2022:
"...based on in vitro testing conducted in collaboration with National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) scientists. Researchers at Rutgers University have also shown Brilacidin inhibited in vitro the Gamma (P.1) and Alpha (B.1.1.7) variants of SARS-CoV-2."
https://www.ipharminc.com/press-release/2022/6/23/innovation-pharmaceuticals-reports-brilacidin-inhibits-omicron-delta-gamma-and-alpha-sars-cov-2-variants-based-on-in-vitro-testing-by-nihniaid-sponsored-and-rutgers-university-researchers
this was from June 28, 2022 company PR:
"Research was performed by scientists at George Mason University’s Center for Infectious Disease Research (formerly NCBID)...
Brilacidin has been researched by NIH/NIAID-sponsored and other academic collaborators as a novel broad-spectrum antiviral drug candidate. A review article is being prepared on Brilacidin based on this research and on results from the Company’s Phase 2 clinical trial (NCT04784897) of intravenous Brilacidin in moderate-to-severe hospitalized cases of COVID-19."
https://www.ipharminc.com/press-release/2022/6/28/innovation-pharmaceuticals-announces-new-antiviral-research-on-brilacidin-in-bunyaviruses-and-alphaviruses-to-be-presented-at-the-2022-military-health-system-research-symposium
And this is from August 5, 2022:
"...in vitro testing initially will be conducted in orthopoxviruses1 (poxviruses) related to monkeypox -- such as vaccinia and cowpox -- through a collaboration with National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID) scientists. Testing in poxviruses builds on earlier NIH/NIAID-affiliated research of Brilacidin in other acutely infectious virus families, including coronaviruses, alphaviruses, flaviviruses, and filoviruses, with a corresponding scientific paper being prepared for publication.
https://www.ipharminc.com/press-release/2022/8/5/innovation-pharmaceuticals-announces-nihniaid-affiliated-researchers-to-evaluate-brilacidins-treatment-potential-against-monkeypox
In response to:
Yep, chart looks coiled, macd turning up, rsi at 60ish.
Just need positive news to trigger volume
My guess: with substantial news like a partnership, and some real money to go with it, we'll likely see 50 million + shares traded in one day.
The SP will get dramatically repriced with even $20-30 million upfront.
To repeat: why would Leo go to the trouble and expense of a Current Provider/Payer Analysis of Brilacidin for Oral Mucositis, if there were no interest? The level of detail provided here is striking:
https://www.ipharminc.com/press-release/2022/7/22/provider-and-payer-analysis-supports-potential-commercialization-of-innovation-pharmaceuticals-brilacidin-as-a-novel-oral-mucositis-drug-candidate
The ruse of "Leo keeping his paycheck coming" has worn thin in the light of a successful PH-2 clinical trial, with focus delayed by B for Covid and gastrointestinal indications.
Here are some of those "cronies" Mr. Ehrlich has in his corner:
NIH/NIAID
https://www.ipharminc.com/press-release/2022/8/5/innovation-pharmaceuticals-announces-nihniaid-affiliated-researchers-to-evaluate-brilacidins-treatment-potential-against-monkeypox
Rutgers University Researchers
https://www.ipharminc.com/press-release/2022/6/23/innovation-pharmaceuticals-reports-brilacidin-inhibits-omicron-delta-gamma-and-alpha-sars-cov-2-variants-based-on-in-vitro-testing-by-nihniaid-sponsored-and-rutgers-university-researchers
Publication of Peer-Review Article in the Journal of Medical Virology on Anti-Coronavirus Properties of Brilacidin
https://www.ipharminc.com/press-release/2022/3/15/innovation-pharmaceuticals-announces-publication-of-peer-review-article-in-the-journal-of-medical-virology-on-anti-coronavirus-properties-of-brilacidin
Can't wait to see who the next "cronies" are. Many shareholders are banking on it too!!
in response to
IPIX is subject to the OTC "Marketplace," which is not a regulated exchange in the same way the NYSE or Nasdaq are.
Thus, dislocations in price are more common, which agrees with your "The market may not always be right..." part.
"the price is always the price" is common sense and literally says nothing new, i.e. a tautology.
"The market determines it." (see the first two sentences, above)
in response to
Thanks for your chart and TA, it looks like the 50day will cross the 200day average soon, if the price keeps inching up as it has been. Then again, something bigger could be in store for next week, given the large block trade and somewhat higher volume today.
And BTW, that large block must have been a miracle "sell" to move the share price from .042 to .045 LOL
It cannot be denied that Someone Bought those shares... All of them, in one fell swoop!
Would rather see sustained buying, unless of course "somebody knows something" lol
Check out level 2 quotes. Is it a head fake or about ready to explode upward?
I have long speculated that after the initial Alfa Sigma deal, Leo stubbornly held high prices in mind for partnering his other B indications, and this prevented a deal from materializing.
Having a third party payer/provider analysis done should set the stage for realistic negotiations, at least for B-OM.
in response to
Excellent line of reasoning, and lots of speculation as to when the first smaller indication may land a partnership for IPIX.
Because the Provider/Payer analysis was recently completed for B-OM, I would guess that one may be first.
Far from being "dead," IPIX has several irons in the fire.
Longs want Leo to "strike while the iron is hot," and the coals seem to be getting hotter recently.